Pay in 4 interest-free payments of $7.36 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Insurance coverage for BPC-157 remains limited in 2026, with most patients paying out-of-pocket for treatment
The TRAVERSE triala large, well-regarded study on TRTdidnt find a significant benefit in preventing worsening insulin resistance in men with prediabetes
However, the amount is extremely small and is not considered harmful
Safety Risks Unknown long-term safety : Effects on human tissues, including potential for fibrosis or unwanted angiogenesis, are not known
BPC-157 Safety Profile BPC-157 has demonstrated a favorable safety profile in preclinical studies, with no significant toxicity reported even at high doses in animal models (5)
Clinical evaluations and lab tests help us see if the treatment is effective and if we need to make changes
US$ 29.94
US$ 25.22
US$ 27.68
US$ 26.31
US$ 23.06
US$ 29.26
